CC-93538
Drug
Celgene Corporation
Total Payments
$797,575
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $797,575 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $797,575 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of CC-93538 in Healthy Japanese and Caucasian Adult Subjects (CC-93538-CP-001) | Celgene Corporation | $797,575 | 0 |
Top Doctors Receiving Payments for CC-93538
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Anaheim, CA | $797,575 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $797,575
Product Information
- Type Drug
- Total Payments $797,575
- Total Doctors 0
- Transactions 1
About CC-93538
CC-93538 is a drug associated with $797,575 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $797,575 was paid across 1 transactions to 0 doctors.
The most common payment nature for CC-93538 is "Unspecified" ($797,575, 100.0% of total).
CC-93538 is associated with 1 research study, including "A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of CC-93538 in Healthy Japanese and Caucasian Adult Subjects (CC-93538-CP-001)" ($797,575).